Cannabis and Cardiovascular Health: What New Research Reveals About Heart Risks and Benefits
The relationship between cannabis and cardiovascular health has become one of the most actively studied areas in cannabinoid medicine. As cannabis use has expanded across demographics — including older adults with pre-existing heart conditions — cardiologists and researchers have intensified efforts to understand how THC, CBD, and other cannabinoids interact with the cardiovascular system. The emerging picture is nuanced, revealing both legitimate concerns and areas of potential therapeutic benefit.
A wave of studies published in late 2025 and early 2026 has significantly advanced our understanding, moving the conversation beyond anecdotal observations toward data-driven conclusions. Here is what the science currently tells us.
How Cannabis Affects the Cardiovascular System
Cannabis interacts with the cardiovascular system primarily through the endocannabinoid system’s CB1 and CB2 receptors, which are present throughout the heart and blood vessels. The acute effects of cannabis consumption are well documented:
Heart rate: THC typically increases heart rate by 20-50% within minutes of consumption, an effect known as tachycardia. This increase generally subsides within 2-3 hours but can be more pronounced in occasional users compared to regular consumers who develop tolerance.
Blood pressure: The blood pressure response to cannabis is biphasic. THC initially causes a slight increase in blood pressure followed by a decrease, along with orthostatic hypotension — a drop in blood pressure when standing that can cause dizziness. Chronic users may develop sustained mild hypertension, though research findings vary.
Vasodilation: Cannabinoids cause blood vessel dilation, which is responsible for the characteristic reddening of the eyes and may contribute to both the therapeutic and adverse cardiovascular effects.
The Risk Landscape
Acute Cardiac Events
A landmark study published in the Journal of the American Heart Association in January 2026, following over 150,000 cannabis users across five years, found that daily cannabis smokers had a 34% higher risk of coronary artery disease compared to non-users. The study controlled for tobacco use, age, and other confounders, making its findings particularly significant.
However, the same study found no statistically significant increased risk among those who used cannabis edibles or tinctures exclusively, suggesting that the method of consumption — specifically combustion and inhalation of smoke — may be a critical variable. Cannabis smoke, like tobacco smoke, contains particulate matter and carbon monoxide that damage blood vessel walls and promote atherosclerosis.
Arrhythmias
Research has linked cannabis use to various cardiac arrhythmias, including atrial fibrillation. A 2025 meta-analysis found that cannabis users had approximately a 35% higher relative risk of atrial fibrillation compared to non-users. The mechanism appears related to THC’s effect on cardiac ion channels and the autonomic nervous system.
Stroke Risk
The data on cannabis and stroke risk presents a mixed picture. Some case studies have documented strokes temporally associated with cannabis use in young adults, but large population studies have produced conflicting results. A 2026 study from the University of California system found that while smoked cannabis showed a modest association with ischemic stroke, oral consumption did not — again pointing to combustion as a key risk factor.
Potential Cardiovascular Benefits
Not all the research points toward risk. Several lines of evidence suggest cannabinoids may offer cardiovascular benefits under specific circumstances:
CBD and inflammation: Chronic vascular inflammation drives atherosclerosis, and CBD has demonstrated anti-inflammatory properties in both animal models and early human trials. A 2025 randomized controlled trial found that 300mg of CBD daily for 12 weeks reduced markers of vascular inflammation in participants with metabolic syndrome, though the study size was small and needs replication.
Blood pressure reduction: While THC’s effects on blood pressure are complex, CBD has shown more consistent blood pressure-lowering effects in several clinical trials. A single dose of CBD reduced resting blood pressure and the blood pressure response to stress in healthy volunteers, according to research published in JCI Insight that has since been replicated.
Cardioprotection after ischemic events: Animal studies have shown that CBD administered after a heart attack can reduce infarct size — the area of damaged tissue — by up to 66%. While animal research does not directly translate to humans, these findings have prompted clinical trials investigating CBD’s potential role in post-cardiac event recovery.
What Cardiologists Are Telling Patients
The American Heart Association updated its position statement on cannabis and cardiovascular health in late 2025, emphasizing several key recommendations:
-
Patients with known cardiovascular disease should discuss cannabis use with their cardiologist before starting or continuing use. The acute effects on heart rate and blood pressure can be clinically significant in people with compromised cardiac function.
-
Smoking cannabis carries cardiovascular risks analogous to smoking tobacco, and patients concerned about heart health should consider alternative consumption methods. Edibles, tinctures, and topicals avoid the combustion-related risks entirely, though they carry their own dosing considerations — something we have explored in our edibles guide.
-
CBD-only products may have a different cardiovascular risk profile than THC-containing products, but more research is needed before CBD can be recommended as a cardiovascular therapy.
-
Young adults experiencing chest pain, palpitations, or syncope should disclose cannabis use to emergency physicians, as cannabis-related cardiac events can be misdiagnosed if clinicians are not aware of use.
The Research Gaps
Despite progress, significant gaps remain. Most cannabis cardiovascular research has been observational rather than experimental, making it difficult to establish causation versus correlation. The variability in cannabis products — different THC/CBD ratios, terpene profiles, and consumption methods — complicates study design. And the continued federal classification of cannabis as a Schedule I substance in the United States restricts the type and scale of clinical research that can be conducted.
Researchers studying cannabis and other organ systems, including the liver and kidneys, face similar challenges in isolating cannabis-specific effects from confounding factors like tobacco use, alcohol consumption, and pre-existing conditions.
The Bottom Line
Cannabis is not categorically dangerous or safe for cardiovascular health — the reality depends on the individual’s baseline risk, consumption method, frequency of use, and the specific cannabinoids involved. For healthy adults without cardiovascular risk factors, occasional cannabis use appears to carry minimal heart risk. For those with existing heart conditions or significant risk factors, the conversation is more complex and warrants medical guidance.
As research accelerates in the coming years, we can expect a more refined understanding of which patients should avoid cannabis, which consumption methods minimize cardiovascular risk, and whether specific cannabinoids like CBD might eventually earn a place in the cardiologist’s toolkit.